BioNexus Gene Lab（BGLC）株式概要バイオネクサス・ジーン・ラボ社は、その子会社とともに、マレーシア、インドネシア、ベトナム、その他東南アジア諸国において、工業、医療、家電、航空、自動車、機械、電子製品製造用の化学原料の販売に注力している。 詳細BGLC ファンダメンタル分析スノーフレーク・スコア評価1/6将来の成長0/6過去の実績0/6財務の健全性5/6配当金0/6リスク分析過去1年間で株主の希薄化は大幅に進んだ 意味のある時価総額がありません ( $5M )過去5年間で収益は年間54%減少しました。 すべてのリスクチェックを見るBGLC Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$2.091.1k% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-3m13m2016201920222025202620282031Revenue US$2.8mEarnings US$155.5kAdvancedSet Fair ValueView all narrativesBioNexus Gene Lab Corp. 競合他社Capstone HoldingSymbol: NasdaqCM:CAPSMarket cap: US$4.4mLavoroSymbol: OTCPK:LVRO.FMarket cap: US$4.4mEuro Tech HoldingsSymbol: NasdaqCM:CLWTMarket cap: US$8.6mAmeraMex InternationalSymbol: OTCPK:AMMXMarket cap: US$2.6m価格と性能株価の高値、安値、推移の概要BioNexus Gene Lab過去の株価現在の株価US$2.0952週高値US$15.6052週安値US$1.92ベータ2.191ヶ月の変化-8.33%3ヶ月変化-12.55%1年変化-29.87%3年間の変化-93.95%5年間の変化-99.06%IPOからの変化-95.75%最新ニュースお知らせ • Apr 01BioNexus Gene Lab Corp. announced delayed annual 10-K filingOn 03/31/2026, BioNexus Gene Lab Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.New Risk • Mar 17New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 63% per year over the past 5 years. Shareholders have been substantially diluted in the past year (32% increase in shares outstanding). Market cap is less than US$10m (US$5.32m market cap). Minor Risk Share price has been volatile over the past 3 months (11% average weekly change).New Risk • Dec 14New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 32% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 63% per year over the past 5 years. Shareholders have been substantially diluted in the past year (32% increase in shares outstanding). Market cap is less than US$10m (US$9.81m market cap).Reported Earnings • Nov 17Third quarter 2025 earnings released: US$0.40 loss per share (vs US$0.75 loss in 3Q 2024)Third quarter 2025 results: US$0.40 loss per share (improved from US$0.75 loss in 3Q 2024). Revenue: US$2.54m (down 3.3% from 3Q 2024). Net loss: US$709.0k (loss narrowed 47% from 3Q 2024).お知らせ • Nov 17BioNexus Gene Lab Corp., Annual General Meeting, Dec 24, 2025BioNexus Gene Lab Corp., Annual General Meeting, Dec 24, 2025.お知らせ • Nov 08BioNexus Gene Lab Corp. has filed a Follow-on Equity Offering in the amount of $3.557 million.BioNexus Gene Lab Corp. has filed a Follow-on Equity Offering in the amount of $3.557 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offering最新情報をもっと見るRecent updatesお知らせ • Apr 01BioNexus Gene Lab Corp. announced delayed annual 10-K filingOn 03/31/2026, BioNexus Gene Lab Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.New Risk • Mar 17New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 63% per year over the past 5 years. Shareholders have been substantially diluted in the past year (32% increase in shares outstanding). Market cap is less than US$10m (US$5.32m market cap). Minor Risk Share price has been volatile over the past 3 months (11% average weekly change).New Risk • Dec 14New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 32% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 63% per year over the past 5 years. Shareholders have been substantially diluted in the past year (32% increase in shares outstanding). Market cap is less than US$10m (US$9.81m market cap).Reported Earnings • Nov 17Third quarter 2025 earnings released: US$0.40 loss per share (vs US$0.75 loss in 3Q 2024)Third quarter 2025 results: US$0.40 loss per share (improved from US$0.75 loss in 3Q 2024). Revenue: US$2.54m (down 3.3% from 3Q 2024). Net loss: US$709.0k (loss narrowed 47% from 3Q 2024).お知らせ • Nov 17BioNexus Gene Lab Corp., Annual General Meeting, Dec 24, 2025BioNexus Gene Lab Corp., Annual General Meeting, Dec 24, 2025.お知らせ • Nov 08BioNexus Gene Lab Corp. has filed a Follow-on Equity Offering in the amount of $3.557 million.BioNexus Gene Lab Corp. has filed a Follow-on Equity Offering in the amount of $3.557 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offeringお知らせ • Aug 15BioNexus Gene Lab Corp. announced delayed 10-Q filingOn 08/14/2025, BioNexus Gene Lab Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Jun 26Bionexus Gene Lab Corp. Announces CFO Changes, Effective June 17, 2025On June 17, 2025, the Board of Directors of BioNexus Gene Lab Corp. (the “Company”) appointed Ms. Chong Set Fui (Angeline) as the Company’s Chief Financial Officer and Principal Financial Officer, effective immediately. Ms. Chong, age 62, has over 25 years of senior financial leadership experience, including serving as the Chief Financial Officer of Avillion Berhad from 2013 until November 2024. She is a member of the Association of Chartered Certified Accountants (ACCA) and the Malaysian Institute of Accountants (MIA), and brings deep expertise in corporate financial reporting, internal controls, and regional operations oversight. Mr. Su-Leng Tan Lee ceased his role as acting Chief Financial Officer and Principal Financial Officer of the Company.お知らせ • Apr 01BioNexus Gene Lab Corp. announced delayed annual 10-K filingOn 03/31/2025, BioNexus Gene Lab Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.Board Change • Feb 14High number of new and inexperienced directorsThere are 3 new directors who have joined the board in the last 3 years. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. Independent Non-Executive Director Chee Yap is the most experienced director on the board, commencing their role in 2022. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.お知らせ • Jan 03Hearing Panel of Nasdaq Grants Temporary Exception to BioNexus Gene Lab to Regain Compliance with Bid Price RuleOn December 27, 2024, BioNexus Gene Lab Corp. received a written notice from the Nasdaq Hearings Panel indicating that the Company has been granted a temporary exception to regain compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share. The Company has until May 1, 2025, to regain compliance. As part of this compliance plan, the Company intends to effect a reverse stock split, if necessary, no later than April 7, 2025, and has outlined steps to meet this timeline. Failure to regain compliance by May 1, 2025, will result in the delisting of the Company’s common stock from The Nasdaq Capital Market. Additionally, Nasdaq has updated its rules regarding reverse stock splits. Effective January 30, 2025, the Company must notify Nasdaq of specific details, including the date of shareholder approval, at least ten (10) calendar days prior to the anticipated market effective date of the reverse stock split. The Company is taking the necessary steps to ensure compliance with the Bid Price Rule within the granted timeframe and will provide updates as appropriate.お知らせ • Nov 15BioNexus Gene Lab Corp. announced delayed 10-Q filingOn 11/14/2024, BioNexus Gene Lab Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Nov 09BioNexus Gene Lab Submits Formal Request for Hearing Before Nasdaq Hearings Panel to Appeal the Delisting DeterminationOn November 5, 2024, BioNexus Gene Lab Corp. (the "Company") received a notification from the Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company's common stock will be delisted from the Nasdaq Capital Market due to its failure to comply with Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1 per share. The Company had been provided two consecutive 180-day grace periods, ending on November 4, 2024, to regain compliance but was unable to meet the requirement within the designated period. In response, on November 8, 2024, the Company submitted a formal request for a hearing before a Nasdaq Hearings Panel to appeal the delisting determination. The Nasdaq Hearings Department has acknowledged receipt of the Company's hearing request, which stays the suspension of trading of the Company's common stock pending a decision by the Panel. The Company intends to present a compliance plan at the hearing, including potential corrective actions such as a reverse stock split, among other strategic initiatives, to regain compliance with Nasdaq's listing standards.お知らせ • Oct 18Bionexus Gene Lab Corp. Announces Resignation of Wei Foong Lim and Koon Wai Wong as Members of the Board of Directors and Member of the Audit Committee, and A Member of the Corporate Governance and Nominating CommitteeOn October 9, 2024, Mr. Wei Foong Lim and Mr. Koon Wai Wong resigned in their capacities as members of the Board of Directors of BioNexus Gene Lab Corp., effective immediately. Mr. Wong was also a Member of the Audit Committee, and a Member of the Corporate Governance and Nominating Committee.お知らせ • Sep 10BioNexus Gene Lab Corp., Annual General Meeting, Oct 04, 2024BioNexus Gene Lab Corp., Annual General Meeting, Oct 04, 2024.Reported Earnings • Aug 16Second quarter 2024 earnings released: US$0.005 loss per share (vs US$0.018 loss in 2Q 2023)Second quarter 2024 results: US$0.005 loss per share (improved from US$0.018 loss in 2Q 2023). Revenue: US$11.9k (down 100% from 2Q 2023). Net loss: US$93.4k (loss narrowed 64% from 2Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 42 percentage points per year, which is a significant difference in performance.Board Change • Jun 28High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. Independent Non-Executive Director Chee Yap is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.お知らせ • May 10The Nasdaq Stock Market Determines BioNexus Gene Lab Eligible for an Additional 180 Calendar Day Extension Period or Until November 4, 2024 to Regain Compliance with Minimum Bid Price Per Share with Nasdaq Continued Listing Rule 5550(a)(2)On November 6, 2023, BioNexus Gene Lab Corp. (the ‘Company’) reported that it received a letter from the Listing Qualifications Department of the Nasdaq Stock Market (‘Nasdaq’) regarding the Company’s failure to comply with Nasdaq Continued Listing Rule (‘Rule’) 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share. A failure to comply with Rule 5550(a)(2) exists when listed securities fail to maintain a closing bid price of at least $1.00 per share for 30 consecutive business days. Under Rule 5810(c)(3)(A), the Company automatically was provided a period of 180 calendar days, until May 6, 2024, to regain compliance. The Company requested in writing an additional 180-calendar day compliance period after the expiration of the Initial Period to regain compliance with the Nasdaq requirements and informed Nasdaq of its intention to cure the deficiency during any second compliance period extension by effecting a reverse stock split, if necessary. On May 8, 2024, the Company received notification from NASDAQ that, after an analysis of the requirements under Nasdaq Listing Rule 5810 (c)(3)(A), the Staff determined that the Company is eligible for an additional 180 calendar day extension period (the ‘Additional Period’), or until November 4, 2024. If at any time during this 180-day period the closing bid price of the Company’s securities is at least $1.00 for a minimum of ten consecutive business days, the Company’s compliance will be regained. In the event that the Company is not able to cure the bid price deficiency during the Additional Period, the Staff will provide written notice that the Common Stock will be delisted; however, the Company may request a hearing before the Nasdaq Hearings Panel (the ‘Panel’), which request, if timely made, would stay any further suspension or delisting action by the Staff pending the conclusion of the hearing process and expiration of any extension that may be granted by the Panel. Although the Company will use all reasonable efforts to achieve compliance with Rule 5550(a)(2), there can be no assurance that the Company will be able to regain compliance with that rule or will otherwise be in compliance with other Nasdaq listing criteria.お知らせ • Mar 29BioNexus Gene Lab Corp. announced delayed annual 10-K filingOn 03/28/2024, BioNexus Gene Lab Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.分析記事 • Feb 14BioNexus Gene Lab Corp. (NASDAQ:BGLC) Stocks Shoot Up 234% But Its P/S Still Looks ReasonableDespite an already strong run, BioNexus Gene Lab Corp. ( NASDAQ:BGLC ) shares have been powering on, with a gain of...Board Change • Feb 14High number of new and inexperienced directorsThere are 8 new directors who have joined the board in the last 3 years. The company's board is composed of: 8 new directors. No experienced directors. No highly experienced directors. President & Director Yee Wong is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.お知らせ • Jan 17Soo Kow Lai Provides Information to Shareholders of BioNexus Gene Lab CorpOn January 17, 2024, Soo Kow Lai, Chan Chong Wong, Liong Tai Tan, Too Kam Tham, Kim Hai Wong announced that on December 11, 2023, Soo Kow Lai, Chan Chong Wong, Liong Tai Tan, Too Kam Tham, Kim Hai Wong executed a Written Consent to Action Without Meeting of the Shareholders (the Written Consent) removing the certain Board members and appointing three new board members of the shareholders’ choosing.お知らせ • Nov 15BioNexus Gene Lab Corp. announced delayed 10-Q filingOn 11/14/2023, BioNexus Gene Lab Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Nov 14BioNexus Gene Lab Receives Letter from Nasdaq Regarding Non-Compliance with Minimum Bid Price Per Share with Nasdaq Continued Listing Rule 5550(a)(2)On November 6, 2023, BioNexus Gene Lab Corp. (the ‘Company’) received a letter from the Listing Qualifications Department of the Nasdaq Stock Market (‘Nasdaq’) regarding the Company’s failure to comply with Nasdaq Continued Listing Rule (‘Rule’) 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share. A failure to comply with Rule 5550(a)(2) exists when listed securities fail to maintain a closing bid price of at least $1.00 per share for 30 consecutive business days. Based on the closing bid price for the last 33 consecutive business days (including, in particular, the period September 20, 2023 through November 3, 2023), the Company failed to meet the aforesaid requirement. Under Rule 5810(c)(3)(A), the Company will be provided a compliance period of 180 calendar days, until May 6, 2024, to regain compliance. If at any time during this 180-day period the closing bid price of the Company’s securities is at least $1.00 for a minimum of ten consecutive business days, the Company’s compliance will be regained. In the event the Company does not regain compliance in the first compliance period, it may be eligible to apply for an additional 180 calendar days to regain compliance. To qualify, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement. The Company will also need to provide written notice of its intention to cure the deficiency during the second compliance period. However, if it appears to the Nasdaq staff that the Company will neither be able nor otherwise eligible to cure the deficiency, it may be subject to delisting by Nasdaq. The letter has no immediate impact on the listing of the Company’s common stock, which will continue to be listed and traded on The Nasdaq Capital Market, subject to the Company’s compliance with the other listing requirements of The Nasdaq Capital Market. Although the Company will use all reasonable efforts to achieve compliance with Rule 5550(a)(2), there can be no assurance that the Company will be able to regain compliance with that rule or will otherwise be in compliance with other Nasdaq listing criteria.Board Change • Nov 14High number of new and inexperienced directorsThere are 8 new directors who have joined the board in the last 3 years. The company's board is composed of: 8 new directors. No experienced directors. No highly experienced directors. President & Director Yee Wong is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.お知らせ • Oct 17+ 1 more updateBioNexus Gene Lab Corp. Appoints Mr. Chi Yuen Leong as the Chief Executive OfficerOn October 12, 2023, the board of directors of the BioNexus Gene Lab Corp. approved the appointment of Mr. Chi Yuen Leong as the Chief Executive Officer, effective October 12, 2023. Mr. Leong, aged 72, has extensive experience in management, commercialization, finance, and the biotechnology industry. He served as the President and director from the Company's inception to August 2022 and has been working with and guiding the Company's successful listing on OTC and Nasdaq. He joined the US Arem Pacific Corporation as the Chief Executive Officer from March 1, 2009, until September 30, 2015. Mr. Leong received a Bachelor of Behavioral Sciences from the University of East Asia, Malaysia. Mr. Leong brings a wide range of business experience, including experience with public companies, to their board of directors.お知らせ • Oct 12+ 1 more updateBioNexus Gene Lab Corp. Announces Resignation of Sook Keng Yeoh as Chief Executive OfficerBioNexus Gene Lab Corp. On October 4, 2023, Mr. Sook Keng Yeoh, the Chief Executive Officer tendered his resignation letter to Bionexus Gene Lab Corp. from his positions at the Company. The Company and Mr. Sook Keng Yeoh agreed that the resignations would be effective October 4, 2023. Mr. Sook Keng Yeoh’s resignation is not due to any disagreement with the Company, the Company’s management, or the Board on any matter relating to the Company’s operations, policies, or practices (financial or otherwise).お知らせ • Sep 09BioNexus Gene Lab Corp. Announces Executive ChangesBioNexus Gene Lab Corp. announced on August 1, 2023, Mr. Liong Tai Tan, the Chief Operating Officer and a member of the Board of Directors, notified Bionexus Gene Lab Corp. (the Company) of his desire to resign from his position at the Company. The Company and Mr. Liong Tai Tan agreed that the resignations would be effective August 31, 2023. Mr. Liong Tai Tan’s resignation is not due to any disagreement with the Company, the Company's management or the Board on any matter relating to the Company’s operations, policies, or practices (financial or otherwise), Mr. Liong Tai Tan informed the Company that he is leaving the Company and the Board of Directors to pursue other commitments. On August 2, 2023, the Board of Directors of the Company approved the appointment of Mr. Lee Su-Leng Tan as the Chief Operating Officer and not a director, effective September 1, 2023. Mr. Tan, aged 40, has over 20 years of extensive experience in industries including Information Systems, Hospitality, Investment Management, Construction, Property Development, Travel, Government Liaison, and Life Sciences, primarily focused on commercialization, finance, and general management. From 2022 to August 2023, Mr. Tan worked as the Chief Commercial Officer for Dryox Health Limited, a startup focused on repurposing drugs for unmet needs in the dermatological space, specifically anticholinergic drugs. From 2017 to August 2023, Mr. Tan worked as the FLO Life Sciences Group’s owner and the Managing Director at Biotechnology Group, focusing on infectious diseases and oncology pre-clinical drug candidates and clinical research. From 2018 to 2019, Mr. Tan was the President of Avillion Berhad, a publicly listed travel and hospitality group with hotels, commercial property, and inbound/outbound travel services.New Risk • Aug 17New major risk - Revenue and earnings growthEarnings have declined by 7.8% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (67% average weekly change). Earnings have declined by 7.8% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (9.9% increase in shares outstanding). Market cap is less than US$100m (US$11.5m market cap).Reported Earnings • Aug 17Second quarter 2023 earnings released: US$0.001 loss per share (vs US$0.01 loss in 2Q 2022)Second quarter 2023 results: US$0.001 loss per share. Revenue: US$2.57m (up 3.3% from 2Q 2022). Net loss: US$259.3k (loss widened 87% from 2Q 2022).New Risk • Jul 26New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 9.9% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (70% average weekly change). Minor Risks Shareholders have been diluted in the past year (9.9% increase in shares outstanding). Market cap is less than US$100m (US$55.7m market cap).Board Change • Jul 21High number of new and inexperienced directorsThere are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. No experienced directors. No highly experienced directors. COO & Executive Director Liong Tan is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.お知らせ • Feb 16BioNexus Gene Lab Corporation has filed an IPO in the amount of $17.25 million.BioNexus Gene Lab Corporation has filed an IPO in the amount of $17.25 million. Security Name: Common Stock Security Type: Common Stockお知らせ • Aug 18+ 1 more updateBionexus Gene Lab Corporation Announces Management ChangesBioNexus Gene Lab Corporation announced that on August 9, 2022, Mr. Soo Kow Lai, the Chairman and director, Mr. Chan Chong Wong, the Chief Executive Officer and director, and Mr. Chi Yuen Leong, the President and director, notified that their desire to resign from their positions at the Company. The Company and Mr. Soo Kow Lai, Mr. Chan Chong Wong, and Mr. Chi Yuen Leong agreed that the resignations would be effective August 12, 2022. Mr. Soo Kow Lai, Mr. Chan Chong Wong, and Mr. Chi Yuen Leong’s resignations do not involve any disagreement on any matter relating to the Company’s operations, policies or practices (financial or otherwise), but were in order to pursue other commitments. On August 9, 2022, the Board of Directors of the Company approved the appointments of Mr. Yeat Min Fong as the Chairman and director, Mr. Sook Keng Yeoh as director, and Ms. Yee Meng Wong as the President and director, effective August 9, 2022. The biographical information of Mr. Yeat Min Fong, Mr. Sook Keng Yeoh, and Mr. Yee Meng Wong are set out below: Mr. Yeat Min Fong, age 43, has over 15 years of extensive experience in the medical industry. From 2020 to 2022, Mr. Fong was the Country General Manager of Malaysia of Doctor Anywhere, responsible for all business activities in the country. From 2014 to 2020, Mr. Fong acted as the General Manager/Medical Director of iHeal Medical Centre, where he performed numerous heart surgeries. Before entering the private medical industry, Mr. Fong engaged in various public hospitals in Malaysia for seven years. Mr. Fong holds a Bachelor of Medicine and Bachelor of Surgery from Manipal Acade MY of Higher Education in Manipal, India and a Master of Business Administration from the University of Cardiff Metropolitan in the UK. Mr. Sook Keng Yeoh, age 63, has over 41 years of extensive experience in management. From 2019 to 2022, Mr. Yeoh served as a director at ADS Sentral Sdn Bhd. From 1999 to 2019, Mr. Yeoh was the Chief Financial Officer and Finance Director of TRC Synergy Bhd., the Chief Executive Officer of TRC Energy Sdn Bhd. and the Executive Director of PetroBru (B) Sdn Bhd., a TRC Group. Mr. Yeoh holds a Bachelor of Commerce in Accounting, Finance, and Systems from the University of New South Wales (Australia) and a Chartered Accountant with the Malaysian Institute of Accountants. Ms. Yee Meng Wong, age 37, has many experiences in the biochemical industry and more than ten years of research experience. From 2016 to 2022, Ms. Wong served as a tutor and a lecturer at Monash University and as a consultant with Biomass Power Plant, Soybean Waste Aerobic Composting Plant, Deep Tech Startup Ultra Battery, and Food Safety & Handling, where she solved a series of biotech issues.お知らせ • Apr 03BioNexus Gene Lab Corporation announced delayed annual 10-K filingOn 04/01/2022, BioNexus Gene Lab Corporation announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • May 18BioNexus Gene Lab Corporation announced delayed 10-Q filingOn 05/17/2021, BioNexus Gene Lab Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Jan 01BioNexus Gene Lab Corporation (OTCPK:BGLC) agreed to acquire Chemrex Corporation Sdn. Bhd.BioNexus Gene Lab Corporation (OTCPK:BGLC) agreed to acquire Chemrex Corporation Sdn. Bhd. on December 24, 2020. Under terms, BioNexus Gene Lab Corporation will issue 68.48 million shares. As of December 31, 2019 Chemrex generated a revenue of $15.6 million and net income of $.30 million. Post acquisition Chemrex will become wholly-owned subsidiary of BioNexus. The transaction is subject to regulatory approvals. The transaction is expected to close on December 31, 2020.株主還元BGLCUS Trade DistributorsUS 市場7D5.8%-3.1%-1.0%1Y-29.9%15.4%23.3%株主還元を見る業界別リターン: BGLC過去 1 年間で15.4 % の収益を上げたUS Trade Distributors業界を下回りました。リターン対市場: BGLCは、過去 1 年間で23.3 % のリターンを上げたUS市場を下回りました。価格変動Is BGLC's price volatile compared to industry and market?BGLC volatilityBGLC Average Weekly Movement8.4%Trade Distributors Industry Average Movement7.3%Market Average Movement7.2%10% most volatile stocks in US Market16.2%10% least volatile stocks in US Market3.2%安定した株価: BGLC 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: BGLCの 週次ボラティリティ は、過去 1 年間で41%から8%に減少しました。会社概要設立従業員CEO（最高経営責任者ウェブサイト201719Lee Tanwww.bionexusgenelab.comバイオネクサス・ジーン・ラボ社は、その子会社とともに、マレーシア、インドネシア、ベトナム、その他東南アジア諸国において、工業、医療、家電、航空、自動車、機械、電子製品製造用の化学原料の販売に注力している。同社は3つのセグメントで事業を展開している：工業用化学品のトレーディング、ゲノム・スクリーニング・サービスの提供、投資持株。汎用樹脂に適したチキソトロピー性・速硬化性不飽和ポリエステル樹脂「ポリエステル樹脂SHCP268」、マリンボートやウォータースライダーの製造に使用される汎用材料「ポリエステル樹脂9509」、引抜き加工用部材として使用される「ポリエステル樹脂2802」など、様々な化学原料製品を提供している。同社の製品は、手すり、ベンチトップ、自動車・航空部品、病院・研究所・工業用クリーンルームのパネル、製造現場で使用される各種器具のカバーなど、さまざまな最終製品の製造に使用されている。バイオマーカーの早期発見を目的とした非侵襲的なリキッドバイオプシー検査を開発・提供。BioNexus Gene Lab Corp.は2017年に法人化され、マレーシアのクアラルンプールを拠点としている。もっと見るBioNexus Gene Lab Corp. 基礎のまとめBioNexus Gene Lab の収益と売上を時価総額と比較するとどうか。BGLC 基礎統計学時価総額US$5.08m収益（TTM）-US$2.90m売上高(TTM)US$5.31m1.0xP/Sレシオ-1.7xPER（株価収益率BGLC は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計BGLC 損益計算書（TTM）収益US$5.31m売上原価US$4.57m売上総利益US$740.93kその他の費用US$3.65m収益-US$2.90m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）-1.20グロス・マージン13.95%純利益率-54.70%有利子負債／自己資本比率1.6%BGLC の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/20 01:58終値2026/05/20 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋BioNexus Gene Lab Corp. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Apr 01BioNexus Gene Lab Corp. announced delayed annual 10-K filingOn 03/31/2026, BioNexus Gene Lab Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
New Risk • Mar 17New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 63% per year over the past 5 years. Shareholders have been substantially diluted in the past year (32% increase in shares outstanding). Market cap is less than US$10m (US$5.32m market cap). Minor Risk Share price has been volatile over the past 3 months (11% average weekly change).
New Risk • Dec 14New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 32% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 63% per year over the past 5 years. Shareholders have been substantially diluted in the past year (32% increase in shares outstanding). Market cap is less than US$10m (US$9.81m market cap).
Reported Earnings • Nov 17Third quarter 2025 earnings released: US$0.40 loss per share (vs US$0.75 loss in 3Q 2024)Third quarter 2025 results: US$0.40 loss per share (improved from US$0.75 loss in 3Q 2024). Revenue: US$2.54m (down 3.3% from 3Q 2024). Net loss: US$709.0k (loss narrowed 47% from 3Q 2024).
お知らせ • Nov 17BioNexus Gene Lab Corp., Annual General Meeting, Dec 24, 2025BioNexus Gene Lab Corp., Annual General Meeting, Dec 24, 2025.
お知らせ • Nov 08BioNexus Gene Lab Corp. has filed a Follow-on Equity Offering in the amount of $3.557 million.BioNexus Gene Lab Corp. has filed a Follow-on Equity Offering in the amount of $3.557 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offering
お知らせ • Apr 01BioNexus Gene Lab Corp. announced delayed annual 10-K filingOn 03/31/2026, BioNexus Gene Lab Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
New Risk • Mar 17New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 63% per year over the past 5 years. Shareholders have been substantially diluted in the past year (32% increase in shares outstanding). Market cap is less than US$10m (US$5.32m market cap). Minor Risk Share price has been volatile over the past 3 months (11% average weekly change).
New Risk • Dec 14New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 32% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 63% per year over the past 5 years. Shareholders have been substantially diluted in the past year (32% increase in shares outstanding). Market cap is less than US$10m (US$9.81m market cap).
Reported Earnings • Nov 17Third quarter 2025 earnings released: US$0.40 loss per share (vs US$0.75 loss in 3Q 2024)Third quarter 2025 results: US$0.40 loss per share (improved from US$0.75 loss in 3Q 2024). Revenue: US$2.54m (down 3.3% from 3Q 2024). Net loss: US$709.0k (loss narrowed 47% from 3Q 2024).
お知らせ • Nov 17BioNexus Gene Lab Corp., Annual General Meeting, Dec 24, 2025BioNexus Gene Lab Corp., Annual General Meeting, Dec 24, 2025.
お知らせ • Nov 08BioNexus Gene Lab Corp. has filed a Follow-on Equity Offering in the amount of $3.557 million.BioNexus Gene Lab Corp. has filed a Follow-on Equity Offering in the amount of $3.557 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offering
お知らせ • Aug 15BioNexus Gene Lab Corp. announced delayed 10-Q filingOn 08/14/2025, BioNexus Gene Lab Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Jun 26Bionexus Gene Lab Corp. Announces CFO Changes, Effective June 17, 2025On June 17, 2025, the Board of Directors of BioNexus Gene Lab Corp. (the “Company”) appointed Ms. Chong Set Fui (Angeline) as the Company’s Chief Financial Officer and Principal Financial Officer, effective immediately. Ms. Chong, age 62, has over 25 years of senior financial leadership experience, including serving as the Chief Financial Officer of Avillion Berhad from 2013 until November 2024. She is a member of the Association of Chartered Certified Accountants (ACCA) and the Malaysian Institute of Accountants (MIA), and brings deep expertise in corporate financial reporting, internal controls, and regional operations oversight. Mr. Su-Leng Tan Lee ceased his role as acting Chief Financial Officer and Principal Financial Officer of the Company.
お知らせ • Apr 01BioNexus Gene Lab Corp. announced delayed annual 10-K filingOn 03/31/2025, BioNexus Gene Lab Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
Board Change • Feb 14High number of new and inexperienced directorsThere are 3 new directors who have joined the board in the last 3 years. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. Independent Non-Executive Director Chee Yap is the most experienced director on the board, commencing their role in 2022. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Jan 03Hearing Panel of Nasdaq Grants Temporary Exception to BioNexus Gene Lab to Regain Compliance with Bid Price RuleOn December 27, 2024, BioNexus Gene Lab Corp. received a written notice from the Nasdaq Hearings Panel indicating that the Company has been granted a temporary exception to regain compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share. The Company has until May 1, 2025, to regain compliance. As part of this compliance plan, the Company intends to effect a reverse stock split, if necessary, no later than April 7, 2025, and has outlined steps to meet this timeline. Failure to regain compliance by May 1, 2025, will result in the delisting of the Company’s common stock from The Nasdaq Capital Market. Additionally, Nasdaq has updated its rules regarding reverse stock splits. Effective January 30, 2025, the Company must notify Nasdaq of specific details, including the date of shareholder approval, at least ten (10) calendar days prior to the anticipated market effective date of the reverse stock split. The Company is taking the necessary steps to ensure compliance with the Bid Price Rule within the granted timeframe and will provide updates as appropriate.
お知らせ • Nov 15BioNexus Gene Lab Corp. announced delayed 10-Q filingOn 11/14/2024, BioNexus Gene Lab Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Nov 09BioNexus Gene Lab Submits Formal Request for Hearing Before Nasdaq Hearings Panel to Appeal the Delisting DeterminationOn November 5, 2024, BioNexus Gene Lab Corp. (the "Company") received a notification from the Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company's common stock will be delisted from the Nasdaq Capital Market due to its failure to comply with Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1 per share. The Company had been provided two consecutive 180-day grace periods, ending on November 4, 2024, to regain compliance but was unable to meet the requirement within the designated period. In response, on November 8, 2024, the Company submitted a formal request for a hearing before a Nasdaq Hearings Panel to appeal the delisting determination. The Nasdaq Hearings Department has acknowledged receipt of the Company's hearing request, which stays the suspension of trading of the Company's common stock pending a decision by the Panel. The Company intends to present a compliance plan at the hearing, including potential corrective actions such as a reverse stock split, among other strategic initiatives, to regain compliance with Nasdaq's listing standards.
お知らせ • Oct 18Bionexus Gene Lab Corp. Announces Resignation of Wei Foong Lim and Koon Wai Wong as Members of the Board of Directors and Member of the Audit Committee, and A Member of the Corporate Governance and Nominating CommitteeOn October 9, 2024, Mr. Wei Foong Lim and Mr. Koon Wai Wong resigned in their capacities as members of the Board of Directors of BioNexus Gene Lab Corp., effective immediately. Mr. Wong was also a Member of the Audit Committee, and a Member of the Corporate Governance and Nominating Committee.
お知らせ • Sep 10BioNexus Gene Lab Corp., Annual General Meeting, Oct 04, 2024BioNexus Gene Lab Corp., Annual General Meeting, Oct 04, 2024.
Reported Earnings • Aug 16Second quarter 2024 earnings released: US$0.005 loss per share (vs US$0.018 loss in 2Q 2023)Second quarter 2024 results: US$0.005 loss per share (improved from US$0.018 loss in 2Q 2023). Revenue: US$11.9k (down 100% from 2Q 2023). Net loss: US$93.4k (loss narrowed 64% from 2Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 42 percentage points per year, which is a significant difference in performance.
Board Change • Jun 28High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. Independent Non-Executive Director Chee Yap is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
お知らせ • May 10The Nasdaq Stock Market Determines BioNexus Gene Lab Eligible for an Additional 180 Calendar Day Extension Period or Until November 4, 2024 to Regain Compliance with Minimum Bid Price Per Share with Nasdaq Continued Listing Rule 5550(a)(2)On November 6, 2023, BioNexus Gene Lab Corp. (the ‘Company’) reported that it received a letter from the Listing Qualifications Department of the Nasdaq Stock Market (‘Nasdaq’) regarding the Company’s failure to comply with Nasdaq Continued Listing Rule (‘Rule’) 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share. A failure to comply with Rule 5550(a)(2) exists when listed securities fail to maintain a closing bid price of at least $1.00 per share for 30 consecutive business days. Under Rule 5810(c)(3)(A), the Company automatically was provided a period of 180 calendar days, until May 6, 2024, to regain compliance. The Company requested in writing an additional 180-calendar day compliance period after the expiration of the Initial Period to regain compliance with the Nasdaq requirements and informed Nasdaq of its intention to cure the deficiency during any second compliance period extension by effecting a reverse stock split, if necessary. On May 8, 2024, the Company received notification from NASDAQ that, after an analysis of the requirements under Nasdaq Listing Rule 5810 (c)(3)(A), the Staff determined that the Company is eligible for an additional 180 calendar day extension period (the ‘Additional Period’), or until November 4, 2024. If at any time during this 180-day period the closing bid price of the Company’s securities is at least $1.00 for a minimum of ten consecutive business days, the Company’s compliance will be regained. In the event that the Company is not able to cure the bid price deficiency during the Additional Period, the Staff will provide written notice that the Common Stock will be delisted; however, the Company may request a hearing before the Nasdaq Hearings Panel (the ‘Panel’), which request, if timely made, would stay any further suspension or delisting action by the Staff pending the conclusion of the hearing process and expiration of any extension that may be granted by the Panel. Although the Company will use all reasonable efforts to achieve compliance with Rule 5550(a)(2), there can be no assurance that the Company will be able to regain compliance with that rule or will otherwise be in compliance with other Nasdaq listing criteria.
お知らせ • Mar 29BioNexus Gene Lab Corp. announced delayed annual 10-K filingOn 03/28/2024, BioNexus Gene Lab Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
分析記事 • Feb 14BioNexus Gene Lab Corp. (NASDAQ:BGLC) Stocks Shoot Up 234% But Its P/S Still Looks ReasonableDespite an already strong run, BioNexus Gene Lab Corp. ( NASDAQ:BGLC ) shares have been powering on, with a gain of...
Board Change • Feb 14High number of new and inexperienced directorsThere are 8 new directors who have joined the board in the last 3 years. The company's board is composed of: 8 new directors. No experienced directors. No highly experienced directors. President & Director Yee Wong is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
お知らせ • Jan 17Soo Kow Lai Provides Information to Shareholders of BioNexus Gene Lab CorpOn January 17, 2024, Soo Kow Lai, Chan Chong Wong, Liong Tai Tan, Too Kam Tham, Kim Hai Wong announced that on December 11, 2023, Soo Kow Lai, Chan Chong Wong, Liong Tai Tan, Too Kam Tham, Kim Hai Wong executed a Written Consent to Action Without Meeting of the Shareholders (the Written Consent) removing the certain Board members and appointing three new board members of the shareholders’ choosing.
お知らせ • Nov 15BioNexus Gene Lab Corp. announced delayed 10-Q filingOn 11/14/2023, BioNexus Gene Lab Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Nov 14BioNexus Gene Lab Receives Letter from Nasdaq Regarding Non-Compliance with Minimum Bid Price Per Share with Nasdaq Continued Listing Rule 5550(a)(2)On November 6, 2023, BioNexus Gene Lab Corp. (the ‘Company’) received a letter from the Listing Qualifications Department of the Nasdaq Stock Market (‘Nasdaq’) regarding the Company’s failure to comply with Nasdaq Continued Listing Rule (‘Rule’) 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share. A failure to comply with Rule 5550(a)(2) exists when listed securities fail to maintain a closing bid price of at least $1.00 per share for 30 consecutive business days. Based on the closing bid price for the last 33 consecutive business days (including, in particular, the period September 20, 2023 through November 3, 2023), the Company failed to meet the aforesaid requirement. Under Rule 5810(c)(3)(A), the Company will be provided a compliance period of 180 calendar days, until May 6, 2024, to regain compliance. If at any time during this 180-day period the closing bid price of the Company’s securities is at least $1.00 for a minimum of ten consecutive business days, the Company’s compliance will be regained. In the event the Company does not regain compliance in the first compliance period, it may be eligible to apply for an additional 180 calendar days to regain compliance. To qualify, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement. The Company will also need to provide written notice of its intention to cure the deficiency during the second compliance period. However, if it appears to the Nasdaq staff that the Company will neither be able nor otherwise eligible to cure the deficiency, it may be subject to delisting by Nasdaq. The letter has no immediate impact on the listing of the Company’s common stock, which will continue to be listed and traded on The Nasdaq Capital Market, subject to the Company’s compliance with the other listing requirements of The Nasdaq Capital Market. Although the Company will use all reasonable efforts to achieve compliance with Rule 5550(a)(2), there can be no assurance that the Company will be able to regain compliance with that rule or will otherwise be in compliance with other Nasdaq listing criteria.
Board Change • Nov 14High number of new and inexperienced directorsThere are 8 new directors who have joined the board in the last 3 years. The company's board is composed of: 8 new directors. No experienced directors. No highly experienced directors. President & Director Yee Wong is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
お知らせ • Oct 17+ 1 more updateBioNexus Gene Lab Corp. Appoints Mr. Chi Yuen Leong as the Chief Executive OfficerOn October 12, 2023, the board of directors of the BioNexus Gene Lab Corp. approved the appointment of Mr. Chi Yuen Leong as the Chief Executive Officer, effective October 12, 2023. Mr. Leong, aged 72, has extensive experience in management, commercialization, finance, and the biotechnology industry. He served as the President and director from the Company's inception to August 2022 and has been working with and guiding the Company's successful listing on OTC and Nasdaq. He joined the US Arem Pacific Corporation as the Chief Executive Officer from March 1, 2009, until September 30, 2015. Mr. Leong received a Bachelor of Behavioral Sciences from the University of East Asia, Malaysia. Mr. Leong brings a wide range of business experience, including experience with public companies, to their board of directors.
お知らせ • Oct 12+ 1 more updateBioNexus Gene Lab Corp. Announces Resignation of Sook Keng Yeoh as Chief Executive OfficerBioNexus Gene Lab Corp. On October 4, 2023, Mr. Sook Keng Yeoh, the Chief Executive Officer tendered his resignation letter to Bionexus Gene Lab Corp. from his positions at the Company. The Company and Mr. Sook Keng Yeoh agreed that the resignations would be effective October 4, 2023. Mr. Sook Keng Yeoh’s resignation is not due to any disagreement with the Company, the Company’s management, or the Board on any matter relating to the Company’s operations, policies, or practices (financial or otherwise).
お知らせ • Sep 09BioNexus Gene Lab Corp. Announces Executive ChangesBioNexus Gene Lab Corp. announced on August 1, 2023, Mr. Liong Tai Tan, the Chief Operating Officer and a member of the Board of Directors, notified Bionexus Gene Lab Corp. (the Company) of his desire to resign from his position at the Company. The Company and Mr. Liong Tai Tan agreed that the resignations would be effective August 31, 2023. Mr. Liong Tai Tan’s resignation is not due to any disagreement with the Company, the Company's management or the Board on any matter relating to the Company’s operations, policies, or practices (financial or otherwise), Mr. Liong Tai Tan informed the Company that he is leaving the Company and the Board of Directors to pursue other commitments. On August 2, 2023, the Board of Directors of the Company approved the appointment of Mr. Lee Su-Leng Tan as the Chief Operating Officer and not a director, effective September 1, 2023. Mr. Tan, aged 40, has over 20 years of extensive experience in industries including Information Systems, Hospitality, Investment Management, Construction, Property Development, Travel, Government Liaison, and Life Sciences, primarily focused on commercialization, finance, and general management. From 2022 to August 2023, Mr. Tan worked as the Chief Commercial Officer for Dryox Health Limited, a startup focused on repurposing drugs for unmet needs in the dermatological space, specifically anticholinergic drugs. From 2017 to August 2023, Mr. Tan worked as the FLO Life Sciences Group’s owner and the Managing Director at Biotechnology Group, focusing on infectious diseases and oncology pre-clinical drug candidates and clinical research. From 2018 to 2019, Mr. Tan was the President of Avillion Berhad, a publicly listed travel and hospitality group with hotels, commercial property, and inbound/outbound travel services.
New Risk • Aug 17New major risk - Revenue and earnings growthEarnings have declined by 7.8% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (67% average weekly change). Earnings have declined by 7.8% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (9.9% increase in shares outstanding). Market cap is less than US$100m (US$11.5m market cap).
Reported Earnings • Aug 17Second quarter 2023 earnings released: US$0.001 loss per share (vs US$0.01 loss in 2Q 2022)Second quarter 2023 results: US$0.001 loss per share. Revenue: US$2.57m (up 3.3% from 2Q 2022). Net loss: US$259.3k (loss widened 87% from 2Q 2022).
New Risk • Jul 26New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 9.9% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (70% average weekly change). Minor Risks Shareholders have been diluted in the past year (9.9% increase in shares outstanding). Market cap is less than US$100m (US$55.7m market cap).
Board Change • Jul 21High number of new and inexperienced directorsThere are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. No experienced directors. No highly experienced directors. COO & Executive Director Liong Tan is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
お知らせ • Feb 16BioNexus Gene Lab Corporation has filed an IPO in the amount of $17.25 million.BioNexus Gene Lab Corporation has filed an IPO in the amount of $17.25 million. Security Name: Common Stock Security Type: Common Stock
お知らせ • Aug 18+ 1 more updateBionexus Gene Lab Corporation Announces Management ChangesBioNexus Gene Lab Corporation announced that on August 9, 2022, Mr. Soo Kow Lai, the Chairman and director, Mr. Chan Chong Wong, the Chief Executive Officer and director, and Mr. Chi Yuen Leong, the President and director, notified that their desire to resign from their positions at the Company. The Company and Mr. Soo Kow Lai, Mr. Chan Chong Wong, and Mr. Chi Yuen Leong agreed that the resignations would be effective August 12, 2022. Mr. Soo Kow Lai, Mr. Chan Chong Wong, and Mr. Chi Yuen Leong’s resignations do not involve any disagreement on any matter relating to the Company’s operations, policies or practices (financial or otherwise), but were in order to pursue other commitments. On August 9, 2022, the Board of Directors of the Company approved the appointments of Mr. Yeat Min Fong as the Chairman and director, Mr. Sook Keng Yeoh as director, and Ms. Yee Meng Wong as the President and director, effective August 9, 2022. The biographical information of Mr. Yeat Min Fong, Mr. Sook Keng Yeoh, and Mr. Yee Meng Wong are set out below: Mr. Yeat Min Fong, age 43, has over 15 years of extensive experience in the medical industry. From 2020 to 2022, Mr. Fong was the Country General Manager of Malaysia of Doctor Anywhere, responsible for all business activities in the country. From 2014 to 2020, Mr. Fong acted as the General Manager/Medical Director of iHeal Medical Centre, where he performed numerous heart surgeries. Before entering the private medical industry, Mr. Fong engaged in various public hospitals in Malaysia for seven years. Mr. Fong holds a Bachelor of Medicine and Bachelor of Surgery from Manipal Acade MY of Higher Education in Manipal, India and a Master of Business Administration from the University of Cardiff Metropolitan in the UK. Mr. Sook Keng Yeoh, age 63, has over 41 years of extensive experience in management. From 2019 to 2022, Mr. Yeoh served as a director at ADS Sentral Sdn Bhd. From 1999 to 2019, Mr. Yeoh was the Chief Financial Officer and Finance Director of TRC Synergy Bhd., the Chief Executive Officer of TRC Energy Sdn Bhd. and the Executive Director of PetroBru (B) Sdn Bhd., a TRC Group. Mr. Yeoh holds a Bachelor of Commerce in Accounting, Finance, and Systems from the University of New South Wales (Australia) and a Chartered Accountant with the Malaysian Institute of Accountants. Ms. Yee Meng Wong, age 37, has many experiences in the biochemical industry and more than ten years of research experience. From 2016 to 2022, Ms. Wong served as a tutor and a lecturer at Monash University and as a consultant with Biomass Power Plant, Soybean Waste Aerobic Composting Plant, Deep Tech Startup Ultra Battery, and Food Safety & Handling, where she solved a series of biotech issues.
お知らせ • Apr 03BioNexus Gene Lab Corporation announced delayed annual 10-K filingOn 04/01/2022, BioNexus Gene Lab Corporation announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • May 18BioNexus Gene Lab Corporation announced delayed 10-Q filingOn 05/17/2021, BioNexus Gene Lab Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Jan 01BioNexus Gene Lab Corporation (OTCPK:BGLC) agreed to acquire Chemrex Corporation Sdn. Bhd.BioNexus Gene Lab Corporation (OTCPK:BGLC) agreed to acquire Chemrex Corporation Sdn. Bhd. on December 24, 2020. Under terms, BioNexus Gene Lab Corporation will issue 68.48 million shares. As of December 31, 2019 Chemrex generated a revenue of $15.6 million and net income of $.30 million. Post acquisition Chemrex will become wholly-owned subsidiary of BioNexus. The transaction is subject to regulatory approvals. The transaction is expected to close on December 31, 2020.
